Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AL101 for the treatment of ...
Quick Take Passage Bio ( PASG ) has filed to raise $125 million in an IPO of its common stock, according to an S-1 registration statement . The firm is developing genetic treatments for monogenic (single gene) central nervous system [CNS] health conditions. PASG is at pre-clinical stage...
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the closing of its previously announced underwritten public offering of 9,602,500 shares of its common stock at th...
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the underwriters fully exercised their option to purchase an additional 1,252,500 shares of common stock at t...
Alector (NASDAQ: ALEC ) slips 3% premarket on light volume in reaction to its public offering of 8.35M (from ~5.1M) common shares at $25/share. Gross proceeds should be ~$209M. More news on: Alector, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
SOUTH SAN FRANCISCO, Calif., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the pricing of an upsized underwritten public offering of 8,350,000 shares of its common stock at a price of $25.0...
- Phase 1b study of AL003 will enroll approximately 12 Alzheimer’s disease patients to assess safety, pharmacokinetics and pharmacodynamics, and monitor target specific biomarkers SOUTH SAN FRANCISCO, Calif., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a ...
Today, we will study why Alector (ALEC) is a high risk/reward opportunity in 2020. Company overview Alector, Inc. is a clinical-stage biopharmaceutical company that is leveraging immune-neurology for treating neurodegenerative diseases. To date, pharmaceutical companies have to try to re...
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced it intends to offer and sell, subject to market and other conditions, 5,095,000 shares of its common stock in an u...
Co-Diagnostics (NASDAQ: CODX ) +158% readies coronavirus test . More news on: Co-Diagnostics, Inc., Trans World Entertainment Corporation, MarineMax, Inc., Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...
2024-04-16 21:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-18 01:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...